XML 93 R79.htm IDEA: XBRL DOCUMENT
v3.23.2

Liabilities Related to Business Combinations and to Non-Controlling Interests - Additional Information (Details) € in Millions, $ in Millions | 6 Months Ended |  |
--- | --- | --- | ---
Jun. 30, 2023 USD ($) | Jun. 30, 2023 EUR (€) | Dec. 31, 2022 EUR (€)
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items] |  |  |
Fair value of contingent consideration payable |  | € 717 | € 779
Bayer contingent consideration arising from acquisition of Genzyme |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items] |  |  |
Payment to sale of business period | 10 years |  |
Fair value of contingent consideration payable |  | € 13 | 26
Increase in fair value of liability |  | 1.00% |
Bayer contingent consideration arising from acquisition of Genzyme | Top of range |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items] |  |  |
Potentiel payments related to percentage of sales of alemtuzumab | $ | $ 1,250 |  |
MSD contingent consideration (European Vaccines business) |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items] |  |  |
Fair value of contingent consideration payable |  | € 133 | 204
Increase in fair value of liability |  | 1.00% |
Shire contingent consideration arising from acquisition of Translate Bio |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items] |  |  |
Fair value of contingent consideration payable |  | € 389 | 380
Increase in fair value of liability |  | 13.00% |
Contingent consideration arising from acquisition of Amunix |  |  |
Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [Line Items] |  |  |
Fair value of contingent consideration payable |  | € 178 | € 165
Increase in fair value of liability |  | 1.00% |

X
- Definition The amount of contingent liabilities recognised in a business combination. [Refer: Contingent liabilities [member]; Business combinations [member]] + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name IFRS -Number 3 -IssueDate 2022-03-24 -Paragraph B67 -Subparagraph c -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2022-en-r&anchor=para_B67_c&doctype=Appendix&subtype=B -URIDate 2022-03-24 + Details
Name: | ifrs-full_ContingentLiabilitiesRecognisedInBusinessCombination
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Disclosure Of Liabilities Related To Business Combinations And To Noncontrolling Interests [line items] + References No definition available. + Details
Name: | sny_DisclosureOfLiabilitiesRelatedToBusinessCombinationsAndToNoncontrollingInterestsLineItems
Namespace Prefix: | sny_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment to sale of business period. + References No definition available. + Details
Name: | sny_PaymentToSaleOfBusinessPeriod
Namespace Prefix: | sny_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage increase in fair value liabilities. + References No definition available. + Details
Name: | sny_PercentageIncreaseInFairValueLiabilities
Namespace Prefix: | sny_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Potential payments related to percentage of sales. + References No definition available. + Details
Name: | sny_PotentialPaymentsRelatedToPercentageOfSales
Namespace Prefix: | sny_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_BayerContingentPurchaseConsiderationArisingFromAcquisitionOfGenzymeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_MSDContingentConsiderationEuropeanVaccinesBusinessMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_ShireContingentConsiderationArisingFromAcquisitionOfTranslateBioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | ifrs-full_BusinessCombinationsAxis=sny_ContingentConsiderationArisingFromAcquisitionOfAmunixMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |